CHMP Backs Two Pan-Genotypic Antivirals for Hep C

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of two new drugs, Maviret and Vosevi, for the treatment of chronic hepatitis C virus (HCV) infection in adults. Maviret (AbbVie Ltd), administered once daily as three oral tablets, contains the NS3/4A protease inhibitor glecaprevir (100 mg) and the NS5A inhibitor pibrentasvir (40 mg). Vosevi (Gilead Sciences) is a once-daily single

New Zealand: Govt asked to greenlight prison Hep-C testing

The government is being asked to agree to a medical trial to find out how many prisoners have been exposed to Hepatitis C. An estimated 50,000 people in New Zealand have the disease, which is transmitted mainly through intravenous needles or badly sterilised medical equipment. Hepatitis C targets the liver, and can be fatal. Little is known about its prevalence in the prison population, but figures from other countries such as the USA and Ireland sugge

Burlington dental patients told to get tested for hepatitis and HIV

The Halton Regional Health Department in Ontario, Canada says 9,000 past and current patients of a Burlington dental clinic should get tested for infectious diseases. On June 9 the department identified that clients who received dental services at Upper Middle Dental operated by Dr. Vick Handa may have been exposed to improperly cleaned instruments used for procedures. “Improperly cleaned dental instruments carry a low risk of transmitting infectious d

Gilead Receives Approval in Canada for VEMLIDY™ (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

MISSISSAUGA, ON, June 19, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for VEMLIDY™ (tenofovir alafenamide, TAF) 25mg tablets, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. – VEMLIDY is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters C

The Week in Review: June 9 – June 16, 2017

Friday, June 16, 2017 News Recap Brenda’s Story Brenda and her husband were forced onto a journey they never wanted to take. Hepatitis C complications put her into a long coma and almost took her life. With luck, love, a generous stranger's liver, and a new hep C cure, she is not only alive but has returned to life with incredible strength and energy. She hopes her story will convince all baby boomers to get tested for hep C, for everyone who has he...

Transplanting kidneys with Hepatitis C saves patients’ lives, cures disease

"Just because the donor has hepatitis C, their kidney quality may not be impaired, especially if you can cure the virus. Because the disease exerts its effects very slowly, it’s possible that a young donor or someone in the early stages of the disease may have very few health problems that result from HCV, meaning those kidneys are high-quality." More than 97,000 people in the United States are currently awaiting kidney transplants—waits that can often ta...

New Hepatitis C Treatment Option Available for Patients Who Failed DAA Therapy

In a new study published in the New England Journal of Medicine, lead investigator Marc Bourliere, MD, from the Hospital Saint Joseph in Marseilles, and his colleagues conducted 2 phase 3 clinical trials to explore treatment options for those chronically infected with hepatitis C (HCV) who have had no success with DAA therapy. Dr. Bourliere et al’s first trial, POLARIS-1, involved 300 patients with HCV genotype 1 who had previously received a drug combi

The Week in Review: June 2 – June 9, 2017

Friday, June 9, 2017 News Recap Somebody Pinch Me This week saw the release of a report from the Cochrane Collaboration which concluded not only that DAAs were ineffective but that they might also be bad for you and not even cure HCV.  The news item was picked up by various media outlets and was hard to miss (No valid evidence $40,000 miracle drug cures hepatitis C – study).  Thankfully other researchers from around the world jumped in on this poor ...

The Hepatitis C Trust responds to study on hepatitis C treatment

In recent days there has been media coverage of a new study that casts doubt upon the effectiveness of new hepatitis C treatments. Given the potential that the coverage of this study has to mislead patients, The Hepatitis C Trust wishes to make clear that we have fundamental doubts as to the credibility of the research. Along with leading clinicians and scientists, we have written to The Guardian to express our concern. The letter states: We are clinician